Finance

Lists
Why is RCKT down 4.98%?
Dive Deeper
RCKT:NASDAQ
Rocket Pharmaceuticals Inc
$2.48
-4.98%
(-0.13) 1D
$2.49
+0.40% (+0.0100)
Pre-market
Closed: Oct 6, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RCKT...
Open
$2.61
High
$2.62
Low
$2.46
Mkt. cap
267.03M
Avg. vol.
1.79M
Volume
2.28K
52-wk high
$5.45
52-wk low
$2.46
EPS
-$0.18
Beta
0.50
Shares outstanding
109.78M
No. of employees
202
Open
$2.61
High
$2.62
Low
$2.46
Mkt. cap
267.03M
Avg. vol.
1.79M
Volume
2.28K
52-wk high
$5.45
52-wk low
$2.46
EPS
-$0.18
Beta
0.50
Shares outstanding
109.78M
No. of employees
202
News stories
From web sources and news partners
About Rocket Pharmaceuticals Inc
CEO-
Employees202
Founded1999
HeadquartersCranbury, New Jersey, United States
SectorBiotechnology
Websiterocketpharma.com
Analyst ratings
Based on 10 analysts giving stock ratings to RCKT in the past 3 months
Buy
Buy
7
Hold
3
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for RCKT in the last 3 months.
Highest
Current $2.48
$15.00 (+504.84%)
Average
$10.88 (+338.71%)
Lowest
$5.00 (+101.61%)
Analyst
Recommendation
Action
Price target
Projected
Date
Patrick Dolezal
LifeSci Capital
Buy
Maintained
$12.00
+383.9%
10/02/2026
Mani Foroohar
Leerink Partners
Hold
Reiterated
-
-
09/16/2026
Gil Blum
Needham
Buy
Upgraded
$9.00
+262.9%
09/16/2026
Jason Zemansky
Bank of America Securities
Buy
Maintained
$10.00
+303.2%
09/15/2026
Yun Zhong
Wedbush
Buy
Maintained
$15.00
+504.8%
09/15/2026
Keay Nakae
Chardan Capital
Buy
Reiterated
$11.00
+343.5%
09/15/2026
Whitney Ijem
Canaccord Genuity
Buy
Maintained
$10.00
+303.2%
08/12/2026
Michael Ulz
Morgan Stanley
Hold
Reiterated
$5.00
+101.6%
08/12/2026
Joshua Schimmer
Cantor Fitzgerald
Buy
Reiterated
$15.00
+504.8%
08/10/2026
Tara Bancroft
TD Cowen
Hold
Maintained
-
-
08/10/2026
Geulah Livshits
Chardan Capital
Buy
Reiterated
$11.00
+343.5%
05/10/2026
Tessa Romero
J.P. Morgan
Sell
Maintained
-
-
04/02/2026
Richard Law CFA
Goldman Sachs
Sell
Maintained
$3.00
+21%
03/27/2026
Unknown Analyst
Canaccord Genuity
Buy
Maintained
$10.00
+303.2%
03/02/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
02/26/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
34.07M
29.35M
31.45M
29.50M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
18.35M
14.68M
17.06M
17.42M
Operating expense
52.42M
44.03M
48.51M
46.92M
Total operating expenses
52.42M
44.03M
48.51M
46.92M
Operating income
-52.42M
-44.03M
-48.51M
-46.92M
Other non operating income
-
-
-
-
EBT including unusual items
-50.33M
-42.54M
-47.59M
131.84M
EBT excluding unusual items
-52.18M
-43.81M
-48.82M
-47.05M
Income tax expense
-
-
-
8.62M
Effective tax rate
-
-
-
6.54%
Other operating expenses
-
-
-
-
Net income
-50.33M
-42.54M
-47.59M
123.21M
Net profit margin
-
-
-
-
Earnings per share
-0.45
-0.38
-0.42
-0.38
Interest and investment income
709.00K
690.00K
161.00K
347.00K
Interest expense
-473.00K
-473.00K
-473.00K
-473.00K
Net interest expenses
236.00K
217.00K
-312.00K
-126.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-49.18M
-41.81M
-46.36M
-44.82M
Gain or loss from assets sale
-
-
-
-178.19M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps